Photys Therapeutics

Photys Therapeutics’ proprietary bifunctional small molecules platform unlocks fine-tuned control of protein post-translational modifications, going beyond degradation to restore protein function, repair signaling, and amplify endogenous disease-fighting mechanisms. Photys was co-founded by the Broad Institute’s leading bifunctional chemist, Amit Choudhary, and the Longwood Fund, alongside a scientific advisory board comprised of distinguished scientists and drug developers – MIT’s Angela Koehler, Salk’s Tony Hunter, Berkeley’s Dan Nomura, MPM’s Wendy Young, and Dana Farber’s Eric Fischer.

Photys Therapeutics headquartered in United States, North America, operates in the Biotechnology sector. The company focuses on Biotechnology and has secured $300.0M in funding across 4 round(s). With a team of 11-50 employees, Photys Therapeutics is actively contributing to advancements in Biotechnology. Their latest funding round, Series A - Photys Therapeutics, raised $75.0M. Discover more about their projects, partnerships, and impact on our platform.